649 related articles for article (PubMed ID: 19563873)
1. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
2. Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines.
Deshpande MC; Venkateswarlu V; Mantri AH; Gadewar ST
Drug Dev Ind Pharm; 2011 May; 37(5):506-17. PubMed ID: 21126213
[TBL] [Abstract][Full Text] [Related]
3. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
4. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
5. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Choi HG; Jeon JY; Im YJ; Kim Y; Jang H; Kang S; Kim KH; Chae SW; Lee SY; Kim MG
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):55-63. PubMed ID: 24290415
[TBL] [Abstract][Full Text] [Related]
7. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Fukaya N; Mochizuki K; Shimada M; Goda T
Nutrition; 2009 Jun; 25(6):657-67. PubMed ID: 19216056
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Mochizuki K; Fukaya N; Tanaka Y; Fuchigami M; Goda T
Metabolism; 2011 Nov; 60(11):1560-5. PubMed ID: 21550076
[TBL] [Abstract][Full Text] [Related]
9. Changes in α-glucosidase activities along the jejunal-ileal axis of normal rats by the α-glucosidase inhibitor miglitol.
Mochizuki K; Hanai E; Suruga K; Kuranuki S; Goda T
Metabolism; 2010 Oct; 59(10):1442-7. PubMed ID: 20153003
[TBL] [Abstract][Full Text] [Related]
10. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
11. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
[TBL] [Abstract][Full Text] [Related]
12. The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Tanaka Y; Mochizuki K; Fukaya N; Shimada M; Goda T
Br J Nutr; 2009 Jul; 102(2):221-5. PubMed ID: 19138443
[TBL] [Abstract][Full Text] [Related]
13. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
14. A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Sato T; Narita T; Hosoba M; Kakei M; Nanjo H; Uchinami H; Satoh K; Yamamoto Y; Yamada Y
Diabetes Res Clin Pract; 2010 Apr; 88(1):e4-6. PubMed ID: 20122751
[TBL] [Abstract][Full Text] [Related]
15. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
[TBL] [Abstract][Full Text] [Related]
17. Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
Hanato J; Kuriyama K; Mizumoto T; Debari K; Hatanaka J; Onoue S; Yamada S
Int J Pharm; 2009 Dec; 382(1-2):111-6. PubMed ID: 19698772
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
19. Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Li Y; Wen S; Kota BP; Peng G; Li GQ; Yamahara J; Roufogalis BD
J Ethnopharmacol; 2005 Jun; 99(2):239-44. PubMed ID: 15894133
[TBL] [Abstract][Full Text] [Related]
20. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
